Multiparametric magnetic resonance imaging of the prostate: Technical aspects and role in clinical management

Topics in Magnetic Resonance Imaging

Volumn 23, Issue 4, 2014, Pages 243-257

  Costa, Daniel N ^a   Pedrosa, Ivan ^a   Roehrborn, Claus ^a   Rofsky, Neil M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

diagnosis; MRI; prostate cancer; risk stratification; staging

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RISK; CANCER STAGING; CANCER SURGERY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION WEIGHTED IMAGING; ECHO PLANAR IMAGING; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; IMAGE QUALITY; MALE; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHOTODYNAMIC THERAPY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RADIOFREQUENCY ABLATION; RADIOLOGICAL PARAMETERS; RISK ASSESSMENT; SIGNAL NOISE RATIO; TREATMENT OUTCOME; CANCER GRADING; DIAGNOSTIC USE; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS;

CONTRAST MEDIUM;

CONTRAST MEDIA; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NEOPLASM GRADING; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 84905977162     PISSN: 08993459     EISSN: 15361004     Source Type: Journal    
DOI: 10.1097/RMR.0000000000000027     Document Type: Article

References (82)

1. Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. J Clin Oncol. 2005;23:8146-8151. (Pubitemid 46211547)
2. Matlaga BR, Eskew LA, McCullough DL. Prostate biopsy: Indications and technique. J Urol. 2003;169:12-19. (Pubitemid 35461538)
3. Hoffman RM. Clinical practice. Screening for prostate cancer. N Engl J Med. 2011;365:2013-2019.
4. Halpern EJ, Strup SE. Using gray-scale and color and power Doppler sonography to detect prostatic cancer. AJR Am J Roentgenol. 2000;174:623-627. (Pubitemid 30126236)
5. Taira AV, Merrick GS, Galbreath RW, et al. Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting. Prostate Cancer Prostatic Dis. 2010;13:71-77.
6. King CR, McNeal JE, Gill H, et al. Extended prostate biopsy scheme improves reliability of Gleason grading: Implications for radiotherapy patients. Int J Radiat Oncol Biol Phys. 2004;59:386-391. (Pubitemid 38622590)
7. Pinthus JH, Witkos M, Fleshner NE, et al. Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: Implication on outcome. J Urol. 2006;176:979-984. (Pubitemid 44142613)
8. Sonn GA, Chang E, Natarajan S, et al. Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen. Eur Urol. 2013.
9. Costa DN, Pedrosa I, Donato F, Jr, et al. MRI-TRUS Fusion for Targeted Prostate Biopsies: Implications for Diagnosis and Clinical Management. Radiological Society of North America 2013 Scientific Assembly and Annual Meeting. Chicago, IL: RSNA; 2013.
10. Hricak H, Williams RD, Spring DB, et al. Anatomy and pathology of the male pelvis by magnetic resonance imaging. AJR Am J Roentgenol. 1983;141:1101-1110. (Pubitemid 14210836)
11. Cornud F, Delongchamps NB, Mozer P, et al. Value of multiparametric MRI in the work-up of prostate cancer. Curr Urol Rep. 2011.
12. Padhani AR, Miles KA. Multiparametric imaging of tumor response to therapy. Radiology. 2010;256:348-364.
13. Langer DL, van der Kwast TH, Evans AJ, et al. Prostate cancer detection with multi-parametric MRI: Logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. J Magn Reson Imaging. 2009;30:327-334.
14. Kurhanewicz J, Vigneron D, Carroll P, et al. Multiparametric magnetic resonance imaging in prostate cancer: Present and future. Curr Opin Urol. 2008;18:71-77. (Pubitemid 350307535)
15. Delongchamps NB, Rouanne M, Flam T, et al. Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: Combination of T2-weighted, dynamic contrast-enhanced and diffusion-weighted imaging. BJU Int. 2011;107:1411-1418.
16. QayyumA, Coakley FV, Lu Y, et al. Organ-confined prostate cancer: Effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol. 2004;183:1079-1083. (Pubitemid 44185100)
17. Rosen Y, Bloch BN, Lenkinski RE, et al. 3 T MR of the prostate: Reducing susceptibility gradients by inflating the endorectal coil with a barium sulfate suspension. Magn Resonance Med. 2007;57:898-904. (Pubitemid 46709410)
18. Hoeks CM, Barentsz JO, Hambrock T, et al. Prostate cancer: Multiparametric MR imaging for detection, localization, and staging. Radiology. 2011;261:46-66.
19. Kirkham AP, Emberton M, Allen C. How good is MRI at detecting and characterising cancer within the prostate? Eur Urol. 2006;50:1163-1174.
20. CruzM, Tsuda K, Narumi Y, et al. Characterization of low-intensity lesions in the peripheral zone of prostate on pre-biopsy endorectal coil MR imaging. Eur Radiol. 2002;12:357-365. (Pubitemid 36940072)
21. Akin O, Sala E, Moskowitz CS, et al. Transition zone prostate cancers: Features, detection, localization, and staging at endorectal MR imaging. Radiology. 2006;239:784-792. (Pubitemid 43830614)
22. JacobsMA, Ouwerkerk R, Petrowski K, et al. Diffusion-weighted imaging with apparent diffusion coefficient mapping and spectroscopy in prostate cancer. Top Magn Reson Imaging. 2008;19:261-272.
23. Somford DM, Futterer JJ, Hambrock T, et al. Diffusion and perfusion MR imaging of the prostate. Magn Reson Imaging Clin N Am. 2008;16:685-695.
24. Gibbs P, Tozer DJ, Liney GP, et al. Comparison of quantitative T2 mapping and diffusion-weighted imaging in the normal and pathologic prostate. Magn Resonance Med. 2001;46:1054-1058. (Pubitemid 33104291)
25. Kim CK, Park BK, Kim B. High-b-value diffusion-weighted imaging at 3 T to detect prostate cancer: Comparisons between b values of 1, 000 and 2, 000 s/mm2. AJR Am J Roentgenol. 2010;194:W33-W37.
26. Katahira K, Takahara T, Kwee TC, et al. Ultra-high-b-value diffusion-weighted MR imaging for the detection of prostate cancer: Evaluation in 201 cases with histopathological correlation. Eur Radiol. 2011;21:188-196.
27. Ohgiya Y, Suyama J, Seino N, et al. Diagnostic accuracy of ultra-high-b-value 3.0-T diffusion-weighted MR imaging for detection of prostate cancer. Clin Imaging. 2012;36:526-531.
28. Verma S, Rajesh A. A clinically relevant approach to imaging prostate cancer: Self-assessment module. AJR AmJ Roentgenol. 2011;196:S11-S14.
29. Hambrock T, Somford DM, Huisman HJ, et al. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology. 2011;259:453-461.
30. Scherrer B, Gholipour A, Warfield SK. Super-resolution reconstruction to increase the spatial resolution of diffusion weighted images from orthogonal anisotropic acquisitions. Med Image Anal. 2012;16:1465-1476.
31. Gholipour A, Kehtarnavaz N, Scherrer B, et al. On the accuracy of unwarping techniques for the correction of susceptibility-induced geometric distortion in magnetic resonance Echo-planar images. Conf Proc IEEE Eng Med Biol Soc. 2011;2011:6997-7000.
32. Donato FJr, Costa DN, Yuan Q, et al. Geometric distortion in diffusion-weighted MR imaging of the prostate-contributing factors and strategies for improvement. Acad Radiol. 2014;21:817-823.
33. Barentsz JO, Engelbrecht M, Jager GJ, et al. Fast dynamic gadolinium-enhanced MR imaging of urinary bladder and prostate cancer. J Magn Reson Imaging. 1999;10:295-304. (Pubitemid 29463112)
34. Engelbrecht MR, Huisman HJ, Laheij RJ, et al. Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology. 2003;229:248-254. (Pubitemid 37152132)
35. Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR guidelines 2012. Eur Radiol. 2012;22:746-757.
36. Bloch BN, Furman-Haran E, Helbich TH, et al. Prostate cancer: Accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging-initial results. Radiology. 2007;245:176-185. (Pubitemid 47417801)
37. Jager GJ, Ruijter ET, van de Kaa CA, et al. Local staging of prostate cancer with endorectal MR imaging: Correlation with histopathology. AJR Am J Roentgenol. 1996;166:845-852. (Pubitemid 26102064)
38. Cornel EB, Smits GA, Oosterhof GO, et al. Characterization of human prostate cancer, benign prostatic hyperplasia and normal prostate by in vitro 1H and 31P magnetic resonance spectroscopy. J Urol. 1993;150:2019-2024. (Pubitemid 24350856)
39. Weinreb JC, Blume JD, Coakley FV, et al. Prostate cancer: Sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy-results of ACRIN prospective multi-institutional clinicopathologic study. Radiology. 2009;251:122-133.
40. Chelsky MJ, Schnall MD, Seidmon EJ, et al. Use of endorectal surface coil magnetic resonance imaging for local staging of prostate cancer. J Urol. 1993;150:391-395. (Pubitemid 23215877)
41. Bezzi M, Kressel HY, Allen KS, et al. Prostatic carcinoma: Staging with MR imaging at 1.5 T. Radiology. 1988;169:339-346.
42. Villers A, Lemaitre L, Haffner J, et al. Current status of MRI for the diagnosis, staging and prognosis of prostate cancer: Implications for focal therapy and active surveillance. Curr Opin Urol. 2009;19:274-282.
43. Haider MA, van der Kwast TH, Tanguay J, et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol. 2007;189:323-328. (Pubitemid 47195916)
44. Ahmed HU, Kirkham A, Arya M, et al. Is it time to consider a role for MRI before prostate biopsy? Nat Rev Clin Oncol. 2009;6:197-206.
45. deSouza NM, Riches SF, Vanas NJ, et al. Diffusion-weighted magnetic resonance imaging: A potential non-invasive marker of tumour aggressiveness in localized prostate cancer. Clin Radiol. 2008;63:774-782.
46. Rastinehad AR, Baccala AAJr, Chung PH, et al. D'Amico risk stratification correlates with degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging. J Urol. 2011;185:815-820.
47. Donati OF, Mazaheri Y, Afaq A, et al. Prostate cancer aggressiveness: Assessment with whole-lesion histogram analysis of the apparent diffusion coefficient. Radiology. 2013: 130973.
48. Labanaris AP, Zugor V, Takriti S, et al. The role of conventional and functional endorectal magnetic resonance imaging in the decision of whether to preserve or resect the neurovascular bundles during radical retropubic prostatectomy. Scand J Urol Nephrol. 2009;43:25-31.
49. Sciarra A, Barentsz J, Bjartell A, et al. Advances in magnetic resonance imaging: How they are changing the management of prostate cancer. Eur Urol. 2011;59:962-977.
50. Muller BG, van den Bos W, Pinto PA, et al. Imaging modalities in focal therapy: Patient selection, treatment guidance, and follow-up. Curr Opin Urol. 2014;24:218-224.
51. de Rooij M, Hamoen EH, Futterer JJ, et al. Accuracy of multiparametric MRI for prostate cancer detection: A meta-analysis. AJR Am J Roentgenol. 2014;202:343-351.
52. Turkbey B, Mani H, Shah V, et al. Multiparametric 3 T prostate magnetic resonance imaging to detect cancer: Histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. J Urol. 2011;186:1818-1824.
53. Puppo P. Repeated negative prostate biopsies with persistently elevated or rising PSA: A modern urologic dilemma. Eur Urol. 2007;52:639-641. (Pubitemid 47126170)
54. Robertson NL, Emberton M, Moore CM. MRI-targeted prostate biopsy: A review of technique and results. Nat Rev Urol. 2013;10:589-597.
55. Hoeks CM, Schouten MG, Bomers JG, et al. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: Detection of clinically significant prostate cancers. Eur Urol. 2012;62:902-909.
56. Haffner J, Lemaitre L, Puech P, et al. Role of magnetic resonance imaging before initial biopsy: Comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Int. 2011;108:E171-E178.
57. Portalez D, Mozer P, Cornud F, et al. Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients. Eur Urol. 2012;62:986-996.
58. Pinto PA, Chung PH, Rastinehad AR, et al. Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J Urol. 2011;186:1281-1285.
59. Margolis DJ, Raman SS, Chang E, et al. Detection rate for prostate cancer using MRI-ultrasound fusion in a biopsy-naïve population. Radiological Society of North America 2013 Scientific Assembly and Annual Meeting. Chicago, IL: RSNA; 2013.
60. Nix JW, Turkbey B, Hoang A, et al. Very distal apical prostate tumours: Identification on multiparametric MRI at 3 Tesla. BJU Int. 2012;110: E694-E700.
61. Bonekamp D, Jacobs MA, El-Khouli R, et al. Advancements in MR imaging of the prostate: From diagnosis to interventions. Radiographics. 2011;31:677-703.
62. Bloch BN, Rofsky NM, Baroni RH, et al. 3 Tesla magnetic resonance imaging of the prostate with combined pelvic phased-array and endorectal coils; initial experience. Acad Radiol. 2004;11:863-867. (Pubitemid 39006233)
63. McNeal JE, Redwine EA, Freiha FS, et al. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol. 1988;12:897-906. (Pubitemid 19011040)
64. Klotz L. Active surveillance for prostate cancer: For whom? J Clin Oncol. 2005;23:8165-8169. (Pubitemid 46211550)
65. Epstein JI, Chan DW, Sokoll LJ, et al. Nonpalpable stage T1c prostate cancer: Prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol. 1998;160:2407-2411. (Pubitemid 29483051)
66. Gleason DF. Histologic grading of prostate cancer: A perspective. Hum Pathol. 1992;23:273-279.
67. Ploussard G, Salomon L, Xylinas E, et al. Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance-does the risk of misclassification vary according to biopsy criteria? J Urol. 2010;183:539-544.
68. Duffield AS, Lee TK, Miyamoto H, et al. Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails. J Urol. 2009;182:2274-2278.
69. Porten SP, Whitson JM, Cowan JE, et al. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance.J ClinOncol. 2011; 29:2795-2800.
70. Thompson IM, Klotz L. Active surveillance for prostate cancer. JAMA. 2010;304:2411-2412.
71. Lee D, Ahmed H, Moore C, et al. Multiparametric magnetic resonance imaging in the management and diagnosis of prostate cancer: Current applications and strategies. Curr Urol Rep. 2014;15:1-10.
72. Marien A, Gill I, Ukimura O, et al. Target ablation-image-guided therapy in prostate cancer. Urol Oncol. 2014.
73. Hu YP, Ahmed HU, Taylor Z, et al. MR to ultrasound registration for image-guided prostate interventions. Med Image Anal. 2012;16:687-703.
74. Leake JL, Hardman R, Ojili V, et al. Prostate MRI: Access to and current practice of prostate MRI in the United States. J Am Coll Radiol. 2014.
75. Liberman L, Abramson AF, Squires FB, et al. The breast imaging reporting and data system: Positive predictive value of mammographic features and final assessment categories. AJR Am J Roentgenol. 1998;171:35-40. (Pubitemid 28308645)
76. Dickinson L, Ahmed HU, Allen C, et al. Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: Could standardization lead to improved utilization of imaging within the diagnostic pathway? J Magn Reson Imaging. 2013;37:48-58.
77. Rosenkrantz AB, Kim S, Lim RP, et al. Prostate cancer localization using multiparametricMRimaging: Comparison of Prostate Imaging Reporting and Data System (PI-RADS) and Likert scales. Radiology. 2013;269:482-492.
78. Lee SH, Park KK, Choi KH, et al. Is endorectal coil necessary for the staging of clinically localized prostate cancer? Comparison of non-endorectal versus endorectal MR imaging. World J Urol. 2010;28:667-672.
79. Cheung MR, Krishnan K. Interactive deformation registration of endorectal prostate MRI using ITK thin plate splines. Acad Radiol. 2009;16:351-357.
80. EngelbrechtMR, Jager GJ, Laheij RJ, et al. Local staging of prostate cancer using magnetic resonance imaging: A meta-analysis. Eur Radiol. 2002;12:2294-2302. (Pubitemid 36940327)
81. Kim BS, Kim TH, Kwon TG, et al. Comparison of pelvic phased-array versus endorectal coil magnetic resonance imaging at 3 Tesla for local staging of prostate cancer. Yonsei Med J. 2012;53:550-556.
82. Turkbey B, Albert PS, Kurdziel K, et al. Imaging localized prostate cancer: Current approaches and new developments. AJR Am J Roentgenol. 2009;192:1471-1480.